Fate Therapeutics (FATE) Change in Acquisitions & Divestments (2016 - 2026)

Fate Therapeutics (FATE) has 11 years of Change in Acquisitions & Divestments data on file, last reported at $52.6 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 43.18% year-over-year to $52.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $272.0 million (down 14.87% YoY) and the FY2025 annual result came in at $311.9 million, down 5.68% from the prior year.
• Change in Acquisitions & Divestments declined to $52.6 million in Q1 2026, from $66.3 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $190.6 million in Q3 2022 to a low of $52.6 million in Q1 2026.
• A 5-year average of $104.7 million and a median of $95.5 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments soared 118.1% — and 2026, when it tumbled 43.18%.
• Tracing FATE's Change in Acquisitions & Divestments over 5 years: stood at $166.9 million in 2022, then plunged by 42.78% to $95.5 million in 2023, then plunged by 36.21% to $60.9 million in 2024, then climbed by 8.86% to $66.3 million in 2025, then retreated by 20.75% to $52.6 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $52.6 million (Q1 2026), $66.3 million (Q4 2025), and $81.4 million (Q3 2025), per Business Quant data.